Latest Regulatory Updates
Hello and welcome back to the Boyds Regulatory Intelligence Digest. This month we are sharing the latest guidance and key updates from the regulatory agencies - ICH, FDA, EMA, MHRA, EC and NCRI.
To discuss any of these updates, please contact a member of the Boyds Regulatory team who will be happy to help.
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)
The draft ICH E6 (R3) scientific guideline on good clinical practice (GCP) is now open for consultation. The revised guideline addresses the application of GCP to new trial designs, technological innovations and to strengthen a proportionate risk-based approach of its application for clinical trials of medicines to support regulatory and healthcare decision making.
The consultation period ends 26 September 2023.
Food and Drug Administration (FDA)
With its recommendations to modernize clinical trials, the FDA also issued guidance complementing the revised GCP guidance (ICH E6(R3) highlighted above, this includes draft guidance released in May for comment, proposing recommendations for the implementation of decentralized clinical trials for drugs, biological products, and devices. Comments may be submitted until 01 August 2023.
New level 1 final guidance was released on the Nonclinical Evaluation of the Immunotoxic Potential of Pharmaceuticals. The expanded guidance now also includes pharmaceuticals intended to affect the immune system, biopharmaceuticals, and oligonucleotides. Further information relates to assessing the carcinogenicity risk of immunomodulators, methods to assess the risk for adverse immunostimulation (e.g., cytokine release assays), nonanimal methods for assessing dermal sensitization, approaches for assessing the effects of immunotoxicants on pregnancy, and developmental immunotoxicity.
Final guidance on the Content of Premarket Submissions for Device Software Functions is now available, providing information regarding the recommended documentation sponsors should include in premarket submissions for the FDA’s evaluation of the safety and effectiveness of device software functions. The final guidance takes a simplified risk-based approach to help determine the device’s Documentation Level, which is either Basic or Enhanced, and helps to identify the minimum amount of information that would support a premarket submission that includes device software functions.
The FDA issued final guidance to announce and describe its voluntary pilot program for Center for Drug Evaluation and Research (CDER)-regulated oncology drug products used with certain in vitro diagnostic tests. The pilot is intended to provide transparency regarding minimum performance necessary for the in vitro diagnostic tests used with the oncology drug products enrolled into the programme.
European Medicines Agency (EMA)
The revised guideline is now available on Procedural advice on publication of information on withdrawals of applications for marketing authorisation and variations/extensions to marketing authorisations (27 June 2023, R2). The guideline was updated to align it with the Guide to information on human medicines evaluated by EMA.
See also the updated Practical guidance on the application form for centralised type IA and IB variations (24 May 2023, R5)
Draft guidance released for public consultation: The Concept Paper on the development of a Guideline on the quality aspects of mRNA vaccines addresses the manufacturing process, characterisation, specifications and analytical control, plus definition of active substance and finished product for mRNA vaccines for the prevention of infectious disease.
The consultation ends 30 September 2023.
Use of real-world evidence (RWE) in regulatory decision making
EMA published its review on the experience gained from 30 studies managed via the different pathways for RWE generation conducted between September 2021 and February 2023. The report also includes recommendations for identified opportunities and challenges.
A new factsheet is available on the implementation of the Regulation on Health Technology Assessment, which entered into force in 2022 and applies from January 2025.
Newsletter: Human medicines highlights – Issue 170, June 2023
Primarily addressed to organisations representing patients, consumers and healthcare professionals, this newsletter provides a summary of key information relating to medicines for human use.
Small and medium-sized enterprise (SME): The SME Office annual report 2022 is now available, featuring key facts and figures of companies that are registered as SMEs with EMA.
Medicines and Healthcare products Regulatory Agency (MHRA)
National Cancer Research Institute (NCRI)
The NCRI, a UK wide partnership between cancer research funders, has announced that it will be winding down after 22 years because of the risk of “operational failure” due to the uncertainty in the wider economic and research environment.
Established in 2005, Boyds provides a range of expertise and skills central to the development of pharmaceutical and biotechnology medicinal products.
Boyds has offices in Cambridge, Cheshire, Dublin and Pennsylvania.
Copyright © 2023 Boyds, All rights reserved.
Our mailing address is:
Alan Boyd Consultants
Crewe Business Park
Crewe, Cheshire CW1 6GL
You are on our list either because you are a valued contact of ours, or we have worked together in the past, or we could work together in the future, or you have asked to receive these updates. If you do not wish to receive these occasional emails from us, please click on the unsubscribe button or update your preferences.
Unsubscribe from these emails
Update your Email Preferences